Beta Bionics, Inc.

Good afternoon, and welcome to the Beta Bionics Second Quarter 2026 Earnings Conference Call. At this time, all participants are on listen-only mode. After the speaker's presentation, there will be a question-and-answer session, and instructions will follow at that time. As a reminder, please advise that today's conference be recorded. I would like to hand the conference over to Blake Beber, Head of Investment Relations.

Good afternoon, and thank you for joining Beta Bionics Second Quarter 2026 Earnings Call. With me on today's call are Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider. Both the replay of this call and the press release discussing our second quarter 2026 results will be available in the Investor Relations section of our website. Information recorded on this call speaks only as of today, July 29, 2026. Therefore, if you are listening to a replay, any time-sensitive information may no longer be accurate. Also on our website is our supplemental second quarter 2026 earnings presentation and uploaded corporate presentation. We encourage you to refer to those documents for a summary of key metrics and business updates. Before we begin, we would like to remind you that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's expectations about future events, our product pipeline, development timelines, financial performance, and operating plans. Please refer to the cautionary statements in the press release we issued earlier today for a detailed explanation of the inherent limitations of such forward-looking statements. These documents contain and identify important factors that may cause actual results to differ materially from current expectations expressed or implied by our forward-looking statements. Please note that the forward-looking statements made during this call speak only as of today's date, and we undertake no obligation to update them to reflect subsequent events or circumstances except to the extent required by law. With that, I'd now like to hand the call over to Sean.

Thanks, Blake. Good afternoon, everyone, and thank you for joining. Getting down to business, today we're going to cover our financial results for the second quarter, updated guidance for the full year of 2026, and some recent developments in our innovation pipeline. Starting with a brief overview of our Q2 performance, we delivered $32 million in net sales, which grew approximately 38% year over year. Q2 revenue growth was driven predominantly by growth in new patient starts, as well as our growing installed base of users who continued to access their monthly supplies to the islet through the pharmacy channel and who we continue to retain at a high level. The percentage of new patient starts that were reimbursed through the pharmacy channel was a high 30s percentage, similar to the prior quarter. Our gross margin was 59%, expanding 524 basis points year over year. Before I hand the call to Stephen, I want to highlight a very important update for Q2. We published our real-world data on our company website, and it's publicly available for all to see. This data is refreshed continuously and openly in near real-time, without filters or fine print. If an islet user has a provider-reported baseline A1C and at least two weeks of data uploaded to our cloud, they are represented on that dashboard. No exclusions applied. Too often in our industry, it has become the norm to publish real-world data that doesn't show the whole picture. Selected populations, optimized settings, No Baseline Comparators, Short Time Periods, Strict Exclusion Criteria. These are all ways that real-world data in our industry has become disconnected from the real-world experience and unrepresentative of population health statistics. I don't want that point to be missed. Any dataset can be subsegmented to show how well a system worked in a narrow set of users, and then marketed as what that system is capable of. Betabionics believes that all people with diabetes deserve great clinical outcomes with minimal work required. So we're setting a new standard in data transparency. The data you see isn't what our system is capable of in a narrow set of users. The data you see is what our system, in fact, does across our broad population. We believe that this is the right way to share real-world data because we're making it easier for healthcare providers, people with diabetes, Payers, investors, and anyone else who's interested to evaluate our outcomes with confidence. We have received very positive feedback on the dashboard, and we view that feedback as a reflection of the positive experience that the island is delivering on the market today. With that, I'll hand the call over to Stephen to provide some additional detail on our second quarter performance and our full year 2026 guidance. Stephen?

Thanks, Sean. Our revenue performance was mainly driven by new patient starts. and their current revenue generated from our growing pharmacy install base. New patient starts increased more than 10%, but less than 20% compared to the prior quarter, consistent with our expectations. We continued to expand the insulin pump market as approximately 69% of our new patient starts came from people utilizing multiple daily injections prior to starting on ILIT. A high 30s percentage of our new patient starts in Q2 accessed ILIT through the pharmacy channel, consistent with our expectations, and we continue to retain our pharmacy install base at a high level. Moving on to gross margin, Q2 gross margin was 59.0%, declining 45 basis points relative to the prior quarter and increasing 524 basis points relative to Q2 2025. Our gross margin exceeded our expectations, primarily driven by the high margin recurring revenue generated from our pharmacy install base and a lower than expected warranty rate. Importantly, Q2 did not benefit from the kind of one-time tailwind that benefited Q1, so we view 59% as a clean read on our underlying gross margin profile and a solid base for continued expansion. Total operating expenses in the second quarter were $44.5 million, an increase of 37% year-over-year. The increase in sales and marketing expense compared to both the prior quarter and the prior year was driven by the continued expansion of our field sales organization and increased marketing investments. In Q2, we achieved our previously stated goal of expanding by at least 20 sales territories in 2026. We expect these new sales territories to contribute more meaningfully to new patient starts in the second half of the year. On R&D expenses, the increase relative to the prior year is driven by the mint and bi-hormonal projects. The increase in G&A expenses relative to the prior year is driven by continued efforts to scale the company in support of commercial growth and pipeline initiatives. As of June 30, 2026, we have approximately $225 million in cash, cash equivalents in short and long-term investments. We believe we are sufficiently capitalized to fund all of our key initiatives and remain well positioned to generate free cash flow well ahead of historical diabetes peers. I'd now like to discuss our updated full-year 2026 guidance. We are reiterating our guidance for total revenue of $131 million to $136 million, as well as our expectation that 37% to 39% of our new patient starts will be reimbursed through the pharmacy channel. On gross margin, we are raising our full-year outlook to 58.5% to 59.5%, up from our prior guidance of 57.5% to 59.5%. This updated outlook reflects our strong first half performance, the underlying gross margin profile I discussed earlier, and our expectation for continued contributions from our pharmacy install base, along with the increasing manufacturing scale throughout the year. As we set our guidance, we also considered the benefit from one-time tailwinds in Q1, while recognizing that neither Q1 nor Q2 were impacted by meaningful one-time headwinds. Although we do not currently expect any notable headwinds in the second half of the year, we believe it is prudent for our outlook to reflect a variety of potential outcomes. To briefly comment on operating expenses, we expect a modest increase in operating expenses in the second half of the year relative to the first half, driven primarily by higher sales and R&D expenses. The sales expense increase reflects the impact of the sales territories we added during the first half of 2026. which will carry their full cost in the second half of 2026. We do not expect to further expand our field sales organization during the second half of the year. Sean, back to you. Thanks, Steven.

To wrap up the call, I'll briefly touch on our remediation efforts regarding the FDA warning letter we received in late January and then highlight some key updates in our innovation pipeline. Regarding the warning letter, the company has made considerable progress in remediating the systems that we believe were central to the agency's concerns. As we have previously stated, the two major focus points of the warning letter, the complaints handling system, primarily our definition of reportable complaints, as well as our post-market surveillance systems are both heavily revised and we believe will meet the agency's expectations. Now, turning to our pipeline. Starting with Mint, our patch pump in development. We recently updated our expected timeline to achieve full commercial launch by the end of the second quarter of 2027, subject to regulatory clearance by the FTA. This reflects VFC's initial feedback on our mint base pump 510K submission, as well as the significant progress we've made in manufacturing readiness. We recently retired our manual manufacturing line, built out a new clean room, and now have our semi-automated production line operating in that clean room. This marks an important milestone in preparing for commercial scale. As our launch plan is built around these semi-automated lines, We believe we're well positioned to support anticipated demand at full launch and as adoption grows over time. We remain confident in our path to FDA clearance and in our ability to manufacture mint at scale. We believe mint has the potential to redefine the patch pump category and become the leading automated insulin delivery platform in the market, and we're excited by the progress we're making towards bringing it to people living with diabetes. We're excited to really begin having a more in-depth discussion as to what constitutes a good patch pump, or in other words, what users want in a patch pump. We think it's impossible to have this conversation with only one product on the market. It's only when two or more products exist that true comparisons can begin to happen. We're excited for Mint's potential to thrive in that conversation, given our confidence in the architectural decisions that we've made, including the two-part design and, importantly, the steel cannulas. For our bi-hormonal system in development, in Q1, we initiated a Phase 2A visibility trial to stress test and iterate the system. During that trial, we identified two key opportunities to improve the system, one focusing on the glucagon assets excipient profile and the other focusing on the dosing algorithms. Beta Bionics is in a unique position here. We're defining what bi-hormonal glucose management is all about. Is it about greater time and range or complete freedom from hypoglycemia or somewhere in between? It's this conversation that we are exploring, which is our responsibility as the developers of the fundamental technology. We expect these iterations to take less than one year prior to initiating additional Phase IIa trials. We continue to believe the biohormonal system has the potential to be a transformative innovation for people with diabetes, which is why our commitment to the program has never been stronger. Lastly, on our innovation pipeline, I want to cover two opportunities where the island is already being used today by providers and patients, albeit off-label. The first opportunity is in type 2 diabetes, where we estimate that greater than 30% of our new patient starts in Q2 were type 2. We recently gained alignment with the FDA in a pivotal trial design that may enable indication expansion for the islet to include adults with type 2 diabetes. The pivotal trial is being conducted on real-world islet users with type 2 diabetes, and we initiated enrollment in July. We ultimately expect to expand ILATS indications for use to include adults with type 2 diabetes in the U.S. around mid-year 2027, subject to regulatory clearance by the FDA. The second opportunity I want to highlight is pursuing a fully closed-loop indication. I've discussed in the past that a meaningful proportion of ILATS users choose to operate the device off-label in a fully closed-loop manner, meaning they announce less than one meal per day on average. Thank you. Thank you. Thank you. We believe we're building the foundation for a category-leading diabetes technology company. Our commercial business continues to gain momentum. The island is resonating with customers and delivering outstanding clinical outcomes. Our pharmacy strategy is working, and with our expanded field organization, we expect to continue increasing awareness and adoption. Looking ahead, the opportunity becomes even more compelling. We expect Mint to launch in less than a year. are preparing a differentiated patch pump with what we believe is the most advanced insulin dosing algorithm available. Around mid-year 27, we expect to expand the algorithm's indication for use to adults with type 2 diabetes, and beyond that, we plan to raise the bar with our bi-hormonal system. We believe the years ahead represent the most exciting chapter in beta bionics history, and the team is committed to bringing these life-changing solutions to people with diabetes. I want to close today with a heartfelt thank you to our team. As you've seen in today's call, we have a lot of initiatives going on as a company. We believe we have a category-leading product pipeline with a fraction of the resources. Said another way, we believe we're doing more with less, and that is all about our team. I just want to remind each of them that I appreciate it, as does the broader community of people with diabetes. You guys rock. With that, I'd like to thank you all for joining today's call, which will now open for Q&A.

Thank you. At this time, we'll collect the questions and answer the session. As a reminder to ask a question, you'll need to press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Please stand by while we compile your Q&A roster. Now, first question comes from the line of Richard Newmitter of True Securities. The line is now open.

Hey, it's Felipe on for Rich. Just starting with the live portal data, I mean, that's a huge figure that you may be the first one to actually put live patient data up online for providers to see. I guess, like, what are you doing to make sure that prescribing physicians are seeing that data and then just one follow-up?

Yeah, great question, Felipe. We are absolutely telling the healthcare provider community about this. They've always been able to see their own clinics in our healthcare provider portal, so they've had access to this for a while. But in this new portal on the website, you can see the entirety of our user base. But absolutely, we're showing them that with our field sales team. But it's absolutely as much about users and others being able to come and take a look at that data there. You know, people who don't have access to our healthcare provider portal. So I would actually say it's primarily for different audiences.

Great, and then, you know, on mint, you know, some of your competitors have nitpicked the steel cannula. I guess, can you remind us, like, what percent of patients on durable pumps, or if you have an idea of what percent of patients on durable pumps are using steel cannulas versus maybe soft cannulas, and why that maybe isn't really a problem for a patch pump? Thanks for taking questions.

Yeah, that's a good question. I do have an idea of What that mix is with durable pumps. For Beta Bionics, that mix, and I'm not going to give specifics, but I will say for Beta Bionics, that mix is quite a bit more heavy toward the steel cannula side of things. We believe in the durability of those systems. We believe in the comfort of those systems. And I think if you go back and look at the evolution into, quote, soft cannulas, they weren't about comfort. I think there's an underlying expectation that steel must be more... Thank you for joining us. What I would encourage you to do is look at somebody taking an injection with an insulin pen and look at the reaction versus a person inserting a quote soft cannula of any description, whether it be an infusion set or one of the patch pumps that may be available, and then tell me what the reaction was. So there's a lot of things that go into these decisions, but we are firmly I'm convinced that our system is going to be an advantage system from user experience. I want to be real careful here because I don't want to make any claims. But that being said, we have all the beliefs in the world of it, and we look forward to being able to talk in more detail about that. And as I said in the prepared remarks, having that head-to-head comparison, right? Right now, people are criticizing this decision of ours. But what we look forward to is a day when somebody has tried the competition, tried us, and then we just ask them, which one did you prefer? And we know where the answer lies because, you know, you slash we've used both.

Moving for our next question. Our next question comes from the line of Matthew O'Brien of Prepper Center, your line is now open.

Good afternoon. Thanks for taking the questions. Just for starters, Sean, maybe just on the pharmacy side of things here in Q2, I know the new patient start numbers were good through the pharmacy, but the supplies number was a little bit wider than expected. Can you talk about that dynamic? And what I'm really trying to get at is during the back half of the year, should we expect more of the The revenue coming from DME for the full year guide and then maybe starting to flip more aggressively towards the supply side as we head into 27. And then I do the follow-up.

This is Steven. Hey, Matt. The softness that you're seeing in pharmacy supply revenue in the second quarter is driven by what I call a stocking dynamic from our pharmacy customers. And what I mean by this is that our pharmacy customers ended The second quarter with less pharmacy supply inventory on their shelf than they did at the end of Q1. So the patient demand for pharmacy supplies was consistent with our expectation. The retention on the product is still strong. The new patient starts going through that channel. We're in line with our expectations. But the actual revenue can be pretty dramatically impacted based on ordering patterns from the pharmacy customers, and that's what's drove that dynamic. So nothing notable about the actual business and performance from patients.

Okay. Appreciate that. And then, Sean, you know, one of your competitors that's coming into the patch market has kind of put a bogey out there of being able to supply about 10,000 patients when they launch. Is that a guidepost we can use for beta, or do you think we should, you know, anchor to something less than that or even more than that? Thank you.

Yeah, I'm not going to comment at this time on our actual expectations or specifics to our supply or expected supply. Yeah, sorry, it's just something we haven't commented on as of yet.

Well, what we can reiterate that we've said in the past is we have our own expectations by the end of Q2 27 for Mint in terms of what demand will be, and we are anticipating the ability to be able to fulfill that level of demand. So embedded in our Thank you.

Thank you. One moment for our next question. Our next question comes from Patrick Wood of UBS. Your line is now open.

Beautiful. Thanks so much for the questions, guys. I'll keep it to one. You know, you always get all this clinical data and see a ton of it, and I'm sure people appreciate you putting it out there. I'm curious, particularly for type 2 patients, have you been surprised by anything in relation to how they've been using islet, whether it's you know units or you know having more patients who are not exactly basal but let's say higher up the acuity curve rather than somebody using a huge amount of units further down. Is there anything you could learn from the data in that type 2 cohort that surprised you at all in terms of how patients are using it? I hope the question's clear.

Let me clarify in terms of how they're using it are you referring primarily to meal announcements which of course for us is essentially the only interaction that you have. But you did refer to units. I'm not sure if you mean units per day. Yeah, can you clarify, please?

Yeah, just total amounts of units used. You can kind of infer, I guess, obviously type tubing essentially a progressive condition, how far down the curves they are. Does that make any sense?

Oh, yeah. So I think what you're trying to get at is there's, I think, an expectation of type 2 that the farther down the curve you are, the more insulin you use. You're probably trying to get an idea of whether or not we're getting the early stage or late stage Type 2s. You got it. You know, it's a great question, and I don't have off the top of my head average units per day in our Type 2 population, but what I can say is that, you know, we've made a number of design architecture decisions on the product, one of which is our cartridge, which is about 180 units, and you know, that decision has been acceptable to our user base, of course, so That means sort of one of two things. One, either the average units per day is comparatively low, or it means that despite the heavier usage that you're traditionally, you know, you're used to and seeing, our cartridge change procedure is quite acceptable in that group. But with all that being said, you know, I have an idea of it, and it's not insane. I mean, yeah, I don't want to comment specifically. I'm not sure it's I find it more interesting to talk about our meal announcement behavior on Islet users than I do total daily goes. Totally.

I got you. Thanks for the question, guys.

Patrick, congrats on the new gig. Oh, yeah. Really nice to have you covering it.

Appreciate it. Glad to be here. Yeah. Thank you. One moment for our next question. Our next question comes from the line of Torian Bernstein of CPCO. Your line is now open.

Great. Thanks, Ed. Jordan on for John here. I'm just thinking about as the year progresses on new customer starts, you know, a nice beat here relative to our model in 2Q. As we think over to 3Q, you know, should we think about that being a step up from 2Q and maybe a steeper slope 3Q to 4Q? In any color there would be much appreciated.

Hey, Jordan. Yes, Q3 will be a step up from Q2, but the specifics of where a new patient starts will end up or what's embedded in the guidance in terms of new patient starts relative to prior quarters, I don't want to comment on. But, yes, we're expecting a step up. We added more than 20 new territories in the first half of the year. Most of those territories start generating demand for the business in our – New Territory started generating demand for the business in roughly one quarter. And, you know, and again, you'd expect that to make an impact in the third and fourth quarter.

Makes sense. And then my follow-up is just on that pharmacy dynamic that you were, you know, discussing before on the stocking and, you know, it seems to be some less pharmacy supply on the shelf. You know, is that something that you'd call industry-wide or or company specific, just kind of company specific, just kind of in the context of, you know, a new competitor entering that channel here throughout the year, trying to figure out if you could provide some more color on that. Thanks.

It's very company specific is the short answer. If you even look at the history of our pharmacy revenue and is related specifically to supply, The pharmacy stocking dynamic has fluctuated from quarter to quarter, sometimes semi-dramatically, and it's not fully predictable. And so we generally comment proactively if there's a major impact from stocking, but the point is you could have another company selling something similar, one of our competitors selling something similar to similar customers, and our performance wouldn't necessarily dictate what their particular performance Hey everyone, thanks for taking your questions.

Can you talk about what ultimately prompted your strategic decision to pursue the pivotal trial of pilot in Type 2? It seems like you've been getting good traction there without it. And then just as a follow-up, can you confirm whether we should expect Mint to also be commercially available for Type 2 as part of that mid-2027 expected timeline?

Great question, Mike. So we've been commenting for a number of quarters that We had type two plans. We just weren't really commenting on them. And exactly to your point, we have had quite a bit of success in the type two space. And for that reason, we didn't feel it was the right thing to do to go and run a traditional trial in that space with the expense and the timeline and everything else. But we had already seen the outcomes that we were getting in type two. So there was a process of working with the agency to kind of compromise on the right data that was required for ILIT specifically in order to get that indication. And as we commented in prepared remarks, we did come to an agreement on that. We are looking at our current ILIT users, but enrolling them in a trial. So that's really what that was about. But why did we do it at any level? Because we're having a ton of success, but we'd love more. And certainly being able to comment on that and sell it publicly is something that we'd like to be able to do. We've achieved the level of success we have without doing that. So it was the right thing to do for us. And it's a pretty modest investment considering how we've chosen to do it. And yeah, Mint with Type 2. Let me make sure I don't get this wrong. You know, Mint itself, the submission on Mint is an ACE pump submission. The pump side of things have historically been approved for people with insulin-dependent diabetes and illness, right? It's the algorithms that have been specific to type 1 or type 2. So to the extent we get a type 2 indication on our algorithm, that algorithm will be paired with Mint, and yes, Mint at that time would carry a type 2 indication as well. the Mint system writ large, meaning Mint hardware with the ILIT algorithm.

Understood. Thanks very much. Thank you. One moment for our next question. Our next question comes from the line of Matthew Blackman of TD County. Your line is now open.

Good afternoon, everybody. Can you hear me okay?

Yeah, we got you, Matt.

All right. Great, guys. Maybe Sean and Stephen, from a high-level perspective, How did the quarter play out on pumps, the shift? I know you said in line with expectations, but I think you probably appreciate there's a lot of background noise in med tech and utilization with coverage changes and perhaps macro headwinds. Just wondering, are you seeing or hearing any of this in the fields of leading into diabetes at all? And then I've got one follow-up.

Yeah. I'll just reiterate that we did think the quarter's new patient stars performance and revenue performance in line with expectations. There was nothing that we saw about Q2 market dynamics-wise or traction with our product that changed our guidance. So I suppose in that respect, everything was, again, consistent with what we expected, and that includes anything related to public policy that may be a perceived headwind. We're just not seeing any of that.

Okay. I appreciate that. And then, Stephen, I'm going to push a little bit, reflecting on your scripted comments, but also in response to... Thank you. Yeah. Yeah, sorry. What we You want me to go at it again?

No, no, Sean just clarified the question for me. Yeah, so, shoot, now I can't remember. I can't remember. Can you restate the question, Matt? Yeah, sorry, go ahead.

I'll give it another shot. So I think historically, recently, you know, this year you told us to use 2025 as sort of a guidepost from a cadence standpoint, percent pumps shipped per quarter or revenue per quarter. And so I know you don't guide quarterly for the third and the fourth quarter. This year is a little bit different. You've onboarded a bunch of new territories. It takes a little bit of time for them to ramp up productivity. So my question is, as we think about the third and fourth quarter, the shape of the third and fourth quarter for 2026. Is 2025 still the right guidepost to use in terms of how we should think about the rest of the year playing out? Or no, maybe it's a little bit more fourth quarter weighted just given the net dynamics of bringing on a sales force, incremental sales force, and driving productivity gains as they work through the back half of the year.

Gotcha. Yeah, the shape that we saw in 2025, Generally consistent with what we're expecting in 2026. There's two primary factors driving that. One is that the sales territories that we added in the first half of 2026, we expect, and history would suggest this for us, or validate this, I should say, that the territories will start to get more productive in their second, third, and quarters beyond. Meaning, you know, the fourth quarter, they've had a longer tenure. They've been at the beta bionics for longer, and thus we would expect them to be more productive. In addition, fourth quarter tends to be seasonally more favorable relative to Q3. Now, that seasonality is muted for reasons that we've explained in the past, driven by the pharmacy dynamic. But those are kind of the contributing factors, I would say, for how we would see the new patient starts growth in the back half of the year. Okay.

Thank you very much, guys.

Yep, sorry to ask you to clarify there. Thanks, Matt.

Thank you. One moment for our next question. Our next question comes from the line of Jeff Johnson of R.W. Baird. Your line is now open.

Hey, guys. Thanks for taking the question. This is Maggie. I'm for Jeff. I was wondering what you guys are seeing on the competitive front at present. One newer company that has come to market with a fairly sizable sales force just in the past. and then another company that is newly independent and has made improvements on their own front. Are you guys seeing any sort of pause from positions, anything from your field sales reps that it's getting harder to win across accounts? Thanks for taking the question.

Yeah, great question, Maggie. No, I don't really think so. I mean, I think that we're obviously aware of the two competitors that you mentioned or alluded to. In one case, actually I would say in both cases, they represent pretty different products to what Beta Bionics is offering. And I think this is a really important point that I don't want to be missed. We've been continuing to educate the market on what Islet is over the last several years. And it does represent a highly differentiated offering as compared to what some of those other companies are doing, especially the ones that are more on the side where settings are important. And you can see that in some of the sub-segmented data that I referred to in my prepared remarks. If you're talking quite a bit about your outcomes and the settings required to get that, that's exactly what we're not doing. And that's why we see data bionics as a sort of a population health tool, something everybody can get or most people can get a good result with. those other products you mentioned are a little bit the other end of that spectrum they require quite a bit of aggressive interaction and so said another way the target islet patient is not necessarily a person who would really be striving for a system like that in general and we also think that over time though people who actually think they want that kind of system will ultimately realize they don't love managing their diabetes and pivot more our way but That's a long way of answering the question and saying, no, we're not really seeing, you know, they're not pulling our target patient away from us in any way. Not seeing it.

Thanks. Thank you, one moment for our next question. Our next question comes from the line of Michael Podork of Wolf Research. Your line is now open.

Hey, good afternoon. I'm curious for color on the 20 new sales territories. Are these folks opening portions of the country that previously were not open for ILET, or are you splitting geographies, going deeper in key places? What's those 20? How are they focused, and what is similar or different to the mandate for the existing prep bases?

Yeah, good question, Mike. So the way I would describe it is this. Beta Bionics really hasn't had much what we call white space, meaning areas without a sales rep at all, for quite a while at this point. So from that perspective, all of these new territories do represent territory cuts. However, it is also true that if you're a rep with a large territory, especially geographically large territory, You're going to have a very hard time getting to some of your target accounts, right? You're going to be focused more in, you know, the large city nearest your home, for example. So, from that perspective, this will ultimately be, will ultimately result in stores that never had a rep visit them starting to visit them at this point, which looks more like a new territory. Where that overlaps is when you cut a territory To the extent that a particular account that was previously writing is now in a new territories area, that rep is incentivized to go visit that account first. They were previously writing. They want to shore up that account. They want to make sure they don't stop. That can be a disruptive experience for that account, and we want to make sure we don't provide that. So they're going to start there, and they're going to then expand into sort of new store sales, if you will. So it falls somewhere in between, you know, just a complete territory cut where the previous territory was completely visited, which wasn't true for us, and a net new territory, which it really isn't there either. Hopefully that's helpful.

Follow-up on that, and then I have my proper follow-up. Has the splitting happened in 2Q, or is that a 2H project?

Yeah, it's happened in 2Q, or in the first half of the year.

The follow-up maybe for Stephen and your prepared remarks, you mentioned lower warranty expense is one of the gross margin good guys. I just want to understand that dynamic. Is there something to read there positively about retention, or that's an overread? I would welcome any further color on that mention. Thank you.

The reason warranty expense has gone down or the warranty rate has gone down is we made the screen stronger. So when we first launched the eyelet, it was shipping with a version of a certain screen strength. And then we've since upgraded the screen to what's called Gorilla Glass 3 to get technical. And now the screen is breaking far less frequently. So that's the impact on gross margin. A second order impact could certainly be retention, although that's a little hard to measure, meaning like, you know, the screen's breaking less often, patients are happier, how less often are they treating? I don't know exactly what that metric is, but yes, absolutely, it's a better patient experience if the islet is breaking less frequently, and that did have a favorable impact on gross margin. Thank you.

Thank you. One moment for our next questions. Our next question comes from the line of Stephanie Algozzi of Peckham, America. Your line is now open.

Hi. Thanks for taking the question. I wanted to follow up on the new patient starts this quarter. It looks like the quarter-over-quarter growth of mid-teens at the midpoint that you shared is below the typical historical trend, Q1 to Q2. Is there anything to call out there, or is it just hard to call history a trend given the initial launch period?

Well, I'm not sure I exactly agree with your math necessarily. You're calling, you know, this particular quarter down relative to a trend in the past. But again, this particular new patient start quarter met our expectations, and I guess I'll just leave it there.

Got it. And then on the mint manufacturing capacity and being able to meet demand at full launch, just Any progress you can share on the confidence you have driving that and, you know, just where you're at now with getting ready for that capacity and what may be left to do?

Yeah, definitely understand what you're trying to get at. I think that, you know, in general we've provided a number of updates lately that are the reasons for our upgraded confidence here. Obviously, we talked about the submission of our 510K. We talked about our clean room construction. We talked about our semi-automated lines being up and running, so much so that we've retired our manual lines. In the past, you've heard me talk about our progression from manual to semi-automated. That would be our launch configuration, followed by fully automated lines that would come on in the future. Those are a very long lead item. So without getting into the exact details of our production rates and our yields and everything else, I think I'll just say that trying to get a little bit of color today on where we are, and obviously we see the underlying numbers, and based on the timelines to launch here, We're feeling good. We're seeing what we need to see at this stage. This is not our first product launch ever, and we're seeing what we need to see to be able to continue to make that statement. So hopefully that's helpful.

Thank you. One moment for our next question. Our next question comes from the line of Jeffrey Coleman of Lanebury Thelma & Co. Your line is now open.

Thank you for taking our questions, Sean and Stephen. Just one follow-up on manufacturing. Could you hypothesize with us regarding margins and how you may think that plays out on Mint and how that might compare to either with the increased efficiency and the automation?

Yeah, just so I make sure I don't answer the wrong question, Jeff, you're asking about Mint's gross margin profile after we launch it?

Yeah, what you would anticipate, yes.

Gotcha. Thank you. Well, without giving you a specific number per gross margin that we're targeting or an outlook that we're targeting, I'll just say this. Manufacturing cost was very much embedded in the design of Mint, meaning the ability to manufacture and the corresponding cost. So, like, meaning the reliability of it yields and the corresponding cost of the actual device itself. And that's why we've done the two-part architecture where we have are reusable portions of the device, which is replaced every two years. And that's where all the expensive components live. And then the actual component of mint that gets thrown away every time a patient changes his or her insulin is actually quite inexpensive in terms of the bill of materials, because all it is is batteries, cannula, the syringe, and the adhesive, with, of course, a few other components. But again, all the expensive components in the reusable portion So at any level of real scale, meaning millions of parts manufactured or millions of mints manufactured annually, our gross margin profile on mint, we believe, will be advantaged relative to the patch pump competition. And again, that's because of our design. And so that gives you some directional sense as to what kind of gross margin profile we're talking about. And also embedded in that, too, is The CapEx associated with getting the mint production capacity to the level that's required. It's reasonably CapEx light, especially the first phase of mint manufacturing development where it's semi-automated. That is very CapEx light. There's more labor costs, of course. That's the tradeoff. But then as mint capacity grows in the future and we move to full automation, more CapEx but still reasonably light relative to numbers you're familiar with from our competition and then labor costs Thank you. We'll move on to our next question.

Our next question comes from a line of Richard Neuwitter of SecuritiesEyes.open.

Hey, guys. Sorry, it's Philippe. Just one follow-up. This is like the second or third quarter that multiple durable pump players are moving into the pharmacy channel, so I'm just wondering if you could give us an update. Are you seeing any changes? You're the furthest along of those players. Are you seeing any changes in your conversations with the PDMs? Are PDMs more open to coverage? I guess, like, what kind of changes are you seeing?

Yeah, great question. You know, I think that multiple players moving in here definitely helps everybody. The conversations become more normal at some level. Nobody wants to do anything out of the ordinary, right? So the more of us do it, the more it's going to be easier for those to follow. We did pave this road a little bit, at least on the tube pump side, and that's okay. But, yeah, I mean, we're happy to have everybody. I think that ultimately that, you know, the pharmacy channel benefits people with diabetes. And, yes, it is getting a little easier to do as we do it and as we provide a roadmap to have it done. Are the conversations evolving? Mildly. I guess there's just a little bit more, you know, a little bit more understanding of what it is that we're doing. But beyond that, no. There's no seismic shift here.

Yeah, I think maybe one other point I'd add is that we've always desired to have the islet reimbursed in the pharmacy channel as the predominant reimbursement strategy in the long term. And I think what actually helps that strategy is other tubed insulin pump companies moving towards pharmacy. And in order for that vision that I've just described to be fulfilled, I don't think it can just be Beta Bionics being the only company that's prioritizing pharmacy or preferring pharmacy as their reimbursement path. And so, yes, maybe it creates like in the short run a small bit of like negotiation over time with the PBMs and the decision makers of the PBMs because there's more pump companies. But look, we like our differentiation and our ability to win those discussions. And then in the long term, this is absolutely healthy. for a company like us that wants our product to be reimbursed in pharmacy. And that goes for Islet and Mint, of course.

Thank you. One moment for our next question. Our next question comes from a line of Frank Taganin of Lake Street Capital Markets. Your line is now open.

Great. Thank you. I'll follow up on the pharmacy channel questions in a slightly different context. I know we've talked about in the past one of the gating factors to getting that broadly adopted and having that unconstrained launch is really the pharmacy channel contracting. Can you remind us and walk us through how that process will go once you have that approval or if you need the approval prior to those contracting discussions? And then how should we think about that kind of impacting the launch cadency?

Hey, Frank. Yeah, look, ILIT's position with pharmacy PBMs, meaning the relationships we have, the contracts that we have, and then the underlying health plans is absolutely the runway that will help us get coverage for mint significantly faster than if we didn't already have ILIT on the market. So in some cases, these are the exact same agreements with the PBMs, with the underlying plans, with an amendment to add a new NDC code. In other cases, it's a new agreement, but the point is we've already convinced chief medical officers or the decision makers at these respective accounts of the merits of ILIT clinically and the users and what their experience is on the device, and so there's no new sales process from zero. All we have to do is convince them that what our hardware is, why it's differentiated, why they should cover what the predicate is, and so that's I can't really understate how important that is for us to be able to have coverage that we'll feel good about at launch. Now, I guess CFO answer here. The other side of this is what I don't want you to hear is that we will have the level of pharmacy coverage that our patch pump competitor will have on day one. That will take us time, and I think it's actually really helpful that that road has already been paved that we can follow, but we will not right out of the gate have the same level of coverage that they have. But I think, look, there's other – I'm just going to take a quick moment to make the point how set up Beta Bionics is for Mint and how, like, you know, I guess well-positioned the company is and this plan that we've laid out years ago, how well it's playing out. And pharmacy coverage is only one part of that. But, you know, you think, like, a company like us with a proven algorithm – are proven in terms of clinically that has confidence from healthcare providers, has confidence from patients, truly differentiated in terms of what its value proposition is. We talked about pharmacy reimbursement and how we've already become experts in that particular area that matters. We have a commercial infrastructure in place, a brand that's well recognized, and this is all exactly how you would draw up a launch for a product like Mint. and, you know, I guess if you can't tell, we're kind of, we're excited about it. And I guess, Frank, just coming back to the pharmacy point, I appreciate you asking.

Small follow-up. This is very specific answer to your question, Frank, and I love Stephen's answer there. In answer to your specific question, do we need approval prior to signing these agreements, the answer is sometimes. But we don't need it to go out and start doing the work. And part of that work, as Stephen has said, was laid by ILIT. additional work is being done now. I'll leave it at that.

Okay, that's helpful. And then just a big picture question, and not sure if you'll be comfortable commenting on this or not, but I'll try. How should we think about the leverage profile coming back into the model? Obviously, investment is first and foremost today, and we're seeing OpEx kind of grow at about the same rate of sales, if not sometimes a little bit faster. When should we see that line cross where that revenue growth starts to really outpace the OpEx investment?

I love the question. As you know, I haven't communicated a specific number for where we start generating free cash flow. So I'm not going to today. But look, what's become the expectation for diabetes medtech companies in particular is in terms of what revenue scale or what revenue is required in order for you to start generating free cash. Don't use that when you're thinking about beta bionics. We're in a different universe in terms of what our expectations are for ourselves and what revenue level is required. I guess just also here that profit and free cash flow generation and returning that to shareholders is just a core principle that that are in Sean and I and building companies. And, yeah, I guess I'm just going to have to take my word for it and, you know, look at our history and what we've done, but I won't pick a particular level. We'll start generating free cash, at least for the moment. Fair enough. That's helpful. Thank you.

Thank you. I'm showing no further questions at this time. I'm going to turn it back to Sean Saint for closing remarks.

I'll just say I appreciate everybody's time and understanding today and willingness to dig in. We're excited, and I hope everybody sees that in our comments today. With that, I'll close it.

Thank you for your participation in today's conference. This concludes the program. You may now disconnect.